$PHAR News

Pharming Says FDA Accepts Joenja Application for Younger Children

Pharming Affirms FY2026 Sales Guidance of $405.000M-$425.000M vs $421.375M Est

Pharming Projects FY2026 Total Revenues Of $405M-$425M With 8%-13% Growth Amid Pipeline Investments And Cost Reductions

Pharming Q1 EPS $(0.07) Misses $0.01 Estimate, Sales $72.400M Miss $93.750M Estimate

Pharming Group N.V. (PHAR) Presents at 25th Annual Needham Virtual Healthcare Conference - Slideshow

Canaccord Genuity Initiates Coverage On Pharming with Buy Rating, Announces Price Target of $37

Renta Corporación Real Estate And 2 Other European Penny Stocks To Watch

European Penny Stocks To Watch In April 2026

I.M.D. International Medical Devices And 2 European Penny Stocks To Watch

European Market Insights: Turbomecanica And 2 Other Promising Penny Stocks

Pharming Group to participate in April investor conferences

3 European Penny Stocks With Market Caps Under €600M

High Growth Tech Stocks To Watch In April 2026

Pharming Group announces the filing of its 2025 Annual Report and Form 20-F

UK Penny Stocks To Watch In March 2026

Pharming Group receives positive CHMP opinion for Joenja® (leniolisib) for the treatment of APDS in adult and pediatric patients 12 years and older

Pharming's Joenja Edges Closer To Becoming First EU-Approved APDS Treatment After Positive CHMP Opinion With European Commission Decision Due Q2 2026

Pharos Energy H2 Earnings Call Highlights

We Think Pharming Group's (AMS:PHARM) Robust Earnings Are Conservative

HC Wainwright & Co. Reiterates Buy on Pharming, Maintains $37 Price Target